Biotechnology company Saniona AB (STO:SANION) announced on Monday that Luc Therapeutics, its collaboration partner and a private biotechnology company, has initiated preclinical development for the drug candidate CAD-1883 for ataxia.
The company said Luc Therapeutics has initiated the pre-clinical development with the aim of initiating Phase 1 first man clinical studies in 2018.
Also, Luc Therapeutics will be responsible for further development of compounds identified under the Ataxia programme.
Apart from being a shareholder of Luc Therapeutics, Saniona has rights to royalties on products commercialised by Luc Therapeutics under the Ataxia programme.
Saniona is a research and development company focused on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and treatment of pain.
Nuvalent commences NVL-655 phase 2 clinical trial in subjects with NSCLC and other solid tumours
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
GenSight Biologics reports business and financial update
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials